<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41031804</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1715-5320</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><PubDate><Year>2025</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme</Title><ISOAbbreviation>Appl Physiol Nutr Metab</ISOAbbreviation></Journal><ArticleTitle>Effect of oat &#x3b2;-glucan in managing blood pressure: a randomized cross-over pilot trial.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>9</EndPage><MedlinePgn>1-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1139/apnm-2024-0317</ELocationID><Abstract><AbstractText>Hypertension affects over 1.2 billion adults worldwide. While numerous pharmacological treatments are available for managing hypertension, dietary approaches may also offer beneficial alternatives or complementary strategies. High molecular weight (HMW) &#x3b2;-glucan, a fibre found in oats, may be responsible for reductions in systolic blood pressure. This pilot trial investigated the efficacy of HMW oat &#x3b2;-glucan in reducing systolic and diastolic blood pressure in individuals with mild hypertension. Additionally, changes in heart rate, body weight, waist circumference, and dietary intake, including protein, carbohydrates, fat, and fibre were assessed. This study was conducted virtually during the COVID-19 pandemic. The trial followed a randomized, double-blinded, cross-over design. During the treatment period, participants were provided breakfast cookies made from oats containing 4&#xa0;g/day of HMW oat &#x3b2;-glucan. During the control period, participants received breakfast cookies made primarily from wheat, which does not contain a significant amount of &#x3b2;-glucan (0.12&#xa0;g/day). Twenty-one people completed the trial. Consumption of oat &#x3b2;-glucan breakfast cookies for 4 weeks did not reduce systolic blood pressure (132.71&#xa0;&#xb1;&#xa0;1.92&#xa0;vs. 132.9&#xa0;&#xb1;&#xa0;1.92, <i>p</i>&#xa0;=&#xa0;0.95) or diastolic blood pressure (82.86&#xa0;&#xb1;&#xa0;1.43&#xa0;vs. 82.38&#xa0;&#xb1;&#xa0;1.43, <i>p</i>&#xa0;=&#xa0;0.98) compared to control. Waist circumference (<i>p</i>&#xa0;=&#xa0;0.67), weight (<i>p</i>&#xa0;=&#xa0;0.79), heart rate (<i>p</i>&#xa0;=&#xa0;0.73), and dietary intake (protein (<i>p</i>&#xa0;=&#xa0;29), carbohydrate (<i>p</i>&#xa0;=&#xa0;0.45), fat (<i>p</i> = 12), and fibre (<i>p</i>&#xa0;=&#xa0;0.64)) were unchanged. Our results indicate that oat &#x3b2;-glucan consumption does not affect systolic or diastolic blood pressure compared to a wheat-based control in middle age and older adults with mild hypertension.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iman</LastName><ForeName>Yasmin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, MB, Canada.</Affiliation><Identifier Source="RINGGOLD">8664</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dandeneau</LastName><ForeName>Dianna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, MB, Canada.</Affiliation><Identifier Source="RINGGOLD">8664</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haizhou</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, MB, Canada.</Affiliation><Identifier Source="RINGGOLD">8664</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mollard</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0006-3935-8730</Identifier><AffiliationInfo><Affiliation>Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, MB, Canada.</Affiliation><Identifier Source="RINGGOLD">8664</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>University of Manitoba, Faculty of Agriculture and Food Sciences, Department of Food and Human Nutritional Sciences, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitlock</LastName><ForeName>Reid</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, MB, Canada.</Affiliation><Identifier Source="RINGGOLD">8664</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Agriculture and Agri-Food Canada, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malunga</LastName><ForeName>Lovemore</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Agriculture and Agri-Food Canada, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tangri</LastName><ForeName>Navdeep</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, MB, Canada.</Affiliation><Identifier Source="RINGGOLD">8664</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>University of Manitoba, Max Rady College of Medicine, Department of Internal Medicine, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackay</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0751-1634</Identifier><AffiliationInfo><Affiliation>University of Manitoba, Faculty of Agriculture and Food Sciences, Department of Food and Human Nutritional Sciences, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Netticadan</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Agriculture and Agri-Food Canada, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thandapilly</LastName><ForeName>Sijo Joseph</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-5404-8443</Identifier><AffiliationInfo><Affiliation>Agriculture and Agri-Food Canada, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Appl Physiol Nutr Metab</MedlineTA><NlmUniqueID>101264333</NlmUniqueID><ISSNLinking>1715-5312</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047071">beta-Glucans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004043">Dietary Fiber</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047071" MajorTopicYN="Y">beta-Glucans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018554" MajorTopicYN="Y">Avena</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="Y">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004043" MajorTopicYN="N">Dietary Fiber</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055105" MajorTopicYN="N">Waist Circumference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ambulatory blood pressure</Keyword><Keyword MajorTopicYN="N">beta-glucan</Keyword><Keyword MajorTopicYN="N">diastolic blood pressure</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">oats</Keyword><Keyword MajorTopicYN="N">systolic blood pressure</Keyword></KeywordList><CoiStatement>The authors declare there are no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>8</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41031804</ArticleId><ArticleId IdType="doi">10.1139/apnm-2024-0317</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41031166</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Persimmon leaf extract in dyslipidemia: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1572678</StartPage><MedlinePgn>1572678</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1572678</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2025.1572678</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="UNASSIGNED">This study aims to evaluate the effects of the combined application of <i>Diospyros kaki</i> Thunb. [Ebenaceae; <i>Kaki folium</i>] (Persimmon leaf) extract on lipid profiles in adults and to explore its potential role in preventing and treating lipid disorders and associated diseases, including common comorbidities such as cardiovascular and cerebrovascular diseases, as well as medication-induced dyslipidemia.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">From the inception of the database to 1 November 2024, we retrieved randomized controlled trials (RCTs) from eight English and Chinese databases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 704 articles were retrieved, from which 16 studies were selected for inclusion in the systematic review and meta-analysis. These studies encompassed 1,572 patients, with 790 assigned to the treatment group and 782 to the control group. Among the dyslipidemia patients included in the study, the most common comorbidities were coronary artery disease, hypertension, ischemic cerebrovascular disease, and dyslipidemia induced by olanzapine, among others. Compared with the control group, the use of combined Persimmon leaf extract (PLE) significantly reduced total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, while demonstrating a certain degree of improvement in high-density lipoprotein cholesterol (HDL-C) levels.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">PLE has been shown to be effective in improving blood lipid profiles in patients, suggesting its potential for widespread clinical application. However, the significant heterogeneity observed across existing studies, coupled with the frequent occurrence of methodological flaws, emphasizes the need for well-designed clinical trials with large sample sizes and extended follow-up periods.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="UNASSIGNED">https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=562090, identifier CRD42024562090.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Dong, Chang, Wang, Zhou, Wang, Wang, Sun, Liao, Cui and Guo.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Dong</LastName><ForeName>Chenxuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chang</LastName><ForeName>Tianying</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>EBM Office, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lisha</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaodan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Clinical Basic Medicine of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Yingzi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>EBM Office, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jiajuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>President's Office, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diospyros kaki Thunb. [Ebenaceae, Kaki folium]</Keyword><Keyword MajorTopicYN="N">dyslipidemia</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">persimmon leaf extract</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41031166</ArticleId><ArticleId IdType="pmc">PMC12477231</ArticleId><ArticleId IdType="doi">10.3389/fphar.2025.1572678</ArticleId><ArticleId IdType="pii">1572678</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aradine E., Hou Y., Cronin C. A., Chaturvedi S. (2020). Current status of dyslipidemia treatment for stroke prevention. Curr. Neurol. Neurosci. Rep. 20 (8), 31. 10.1007/s11910-020-01052-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-020-01052-4</ArticleId><ArticleId IdType="pubmed">32572590</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett D. K., Blumenthal R. S., Albert M. A., Buroker A. B., Goldberger Z. D., Hahn E. J., et al. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines. Circulation 140 (11), e596&#x2013;e646. 10.1161/cir.0000000000000678</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000000678</ArticleId><ArticleId IdType="pmc">PMC7734661</ArticleId><ArticleId IdType="pubmed">30879355</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitis M., Lowenstein C. J. (2023). Dyslipidemia. Ann. Intern Med. 176 (6), Itc81&#x2013;Itc96. 10.7326/aitc202306200</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/aitc202306200</ArticleId><ArticleId IdType="pubmed">37307585</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin E. J., Blaha M. J., Chiuve S. E., Cushman M., Das S. R., Deo R., et al. (2017). Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135 (10), e146&#x2013;e603. 10.1161/cir.0000000000000485</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000000485</ArticleId><ArticleId IdType="pmc">PMC5408160</ArticleId><ArticleId IdType="pubmed">28122885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhargava S., de la Puente-Secades S., Schurgers L., Jankowski J. (2022). Lipids and lipoproteins in cardiovascular diseases: a classification. Trends Endocrinol. Metab. 33 (6), 409&#x2013;423. 10.1016/j.tem.2022.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2022.02.001</ArticleId><ArticleId IdType="pubmed">35370062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia H. S., Wandel S., Willeit P., Lesogor A., Bailey K., Ridker P. M., et al. (2024). Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis. Circulation 151, 312&#x2013;321. 10.1161/circulationaha.124.069556</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.124.069556</ArticleId><ArticleId IdType="pmc">PMC11771346</ArticleId><ArticleId IdType="pubmed">39492722</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt M. S., Sultan M. T., Aziz M., Naz A., Ahmed W., Kumar N., et al. (2015). Persimmon (Diospyros kaki) fruit: hidden phytochemicals and health claims. Excli J. 14, 542&#x2013;561. 10.17179/excli2015-159</Citation><ArticleIdList><ArticleId IdType="doi">10.17179/excli2015-159</ArticleId><ArticleId IdType="pmc">PMC4817420</ArticleId><ArticleId IdType="pubmed">27047315</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovascular Disease Branch of the Chinese Medical Association Professional Committee of Cardiac Prevention and Rehabilitation C.A.o.R.M.C.P.C.o.t.C.G.a.G.S. (2020). Chinese guidelines for the primary prevention of cardiovascular diseases. Chin. J. Cardiol. 48 (12), 1000&#x2013;1038. 10.3760/cma.j.cn112148-20201009-00796</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112148-20201009-00796</ArticleId><ArticleId IdType="pubmed">33355747</ArticleId></ArticleIdList></Reference><Reference><Citation>Carli M., Kolachalam S., Longoni B., Pintaudi A., Baldini M., Aringhieri S., et al. (2021). Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel) 14 (3), 238. 10.3390/ph14030238</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14030238</ArticleId><ArticleId IdType="pmc">PMC8001502</ArticleId><ArticleId IdType="pubmed">33800403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheeley M. K., Saseen J. J., Agarwala A., Ravilla S., Ciffone N., Jacobson T. A., et al. (2022). NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J. Clin. Lipidol. 16 (4), 361&#x2013;375. 10.1016/j.jacl.2022.05.068</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2022.05.068</ArticleId><ArticleId IdType="pubmed">35718660</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Liang Y. H., Pei S. C., Feng Y. P., Wei M. (2011a). Effects of flavonoids from persimmon leaves on the activities of hepatic lipoprotein metabolism-related enzymes and antioxidant capacity in rats with hyperlipidemia. Chin. J. Nat. Med. 9 (01), 74&#x2013;77.</Citation></Reference><Reference><Citation>Chen Y. Z., Wu M., Zhang X. B., Yan J. H. (2011b). Effects of flavonoids from persimmon leaves on atherosclerosis in apolipoprotein E-deficient mice. Chin. J. Gerontology 31 (12), 2233&#x2013;2234.</Citation></Reference><Reference><Citation>Chinese Society of Cardiology C.M.A.C.P.a.R.C. Chinese Association of Rehabilitation Medicine Cardiology Committee, Chinese Geriatrics and Gerontology Society Thrombosis Prevention and Treatment Committee, Cardiovascular Medicine Branch Chinese Medical Doctor Association (2023). Chinese guidelines for primary prevention of cardiovascular diseases (primary care version). Chin. J. Cardiol. 51 (4), 343&#x2013;363. 10.3760/cma.j.cn112148-20230106-00014</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112148-20230106-00014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinetti-Gbaguidi G., Baron M., Bouhlel M. A., Vanhoutte J., Copin C., Sebti Y., et al. (2011). Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPAR&#x3b3; and LXR&#x3b1; pathways. Circ. Res. 108 (8), 985&#x2013;995. 10.1161/circresaha.110.233775</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.110.233775</ArticleId><ArticleId IdType="pmc">PMC3319502</ArticleId><ArticleId IdType="pubmed">21350215</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey K. E., Chalasani N. (2014). Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 12 (7), 1077&#x2013;1084. 10.1016/j.cgh.2013.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2013.08.014</ArticleId><ArticleId IdType="pmc">PMC3933450</ArticleId><ArticleId IdType="pubmed">23962548</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R., Laird N. (1986). Meta-analysis in clinical trials. Control Clin. Trials 7 (3), 177&#x2013;188. 10.1016/0197-2456(86)90046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y. (2022). Clinical efficacy of naoxinging capsule combined with levosimendanin the treatment of chronic heart failure. Henan Med. Res. 31 (05), 896&#x2013;899.</Citation></Reference><Reference><Citation>Fareed N., El-Kersh D. M., Youssef F. S., Labib R. M. (2022). Unveiling major ethnopharmacological aspects of genus Diospyros in context to its chemical diversity: a comprehensive overview. J. Food Biochem. 46 (12), e14413. 10.1111/jfbc.14413</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jfbc.14413</ArticleId><ArticleId IdType="pubmed">36136087</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rstermann U., Xia N., Li H. (2017). Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ. Res. 120 (4), 713&#x2013;735. 10.1161/circresaha.116.309326</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.116.309326</ArticleId><ArticleId IdType="pubmed">28209797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gai W. (2020). Primary prevention of cerebrovascular diseases. Chin. J. Neurology 53 (8), 614&#x2013;622. 10.3760/cma.j.cn113694-20200414-00265</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn113694-20200414-00265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Liu J., Liu X., Hao Y., Pan Z., He X., et al. (2025). Persimmon leaf extract ameliorates hyperlipidemia by modulating lipid genes expression and gut microbiota in high-fat-diet-fed mice. J. Sci. Food Agric. 105 (9), 5074&#x2013;5089. 10.1002/jsfa.14248</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jsfa.14248</ArticleId><ArticleId IdType="pubmed">40165393</ArticleId></ArticleIdList></Reference><Reference><Citation>He C., T. Q., He J. X., Wen J., Yin R. L. (2017). Optimization of the prescription for oral disintegrating tablets of persimmon leaf total flavonoid solid dispersion. Tradit. Chin. Pat. Med. 39 (12), 2513&#x2013;2517.</Citation></Reference><Reference><Citation>Higgins J. P., Thompson S. G., Deeks J. J., Altman D. G. (2003). Measuring inconsistency in meta-analyses. BMJ 327 (7414), 557&#x2013;560. 10.1136/bmj.327.7414.557</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J. P., Altman D. G., G&#xf8;tzsche P. C., J&#xfc;ni P., Moher D., Oxman A. D., et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj 343, d5928. 10.1136/bmj.d5928</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong E. L., Liao X. J., Chang F. K. (2017). Effects of naoxinqing tablets on glucose and lipid metabolism in schizophrenia patients treated with olanzapine. J. Mod. Integr. Med. Traditional Chin. West. Med. 26 (15), 1686&#x2013;1687+1692.</Citation></Reference><Reference><Citation>Hong C., Wang X., Xu J., Guo J., Peng H., Zhang Y. (2023). A review: pharmacological effect of natural compounds in Diospyros kaki leaves from the perspective of oxidative stress. Molecules 29 (1), 215. 10.3390/molecules29010215</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules29010215</ArticleId><ArticleId IdType="pmc">PMC10780463</ArticleId><ArticleId IdType="pubmed">38202798</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain A., Shahidi F. (2023). Persimmon leaves: nutritional, pharmaceutical, and industrial potential-a review. Plants (Basel) 12 (4), 937. 10.3390/plants12040937</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/plants12040937</ArticleId><ArticleId IdType="pmc">PMC9965245</ArticleId><ArticleId IdType="pubmed">36840285</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu M. W. a.S. (2012). Effects of flavonoids from persimmon leaves on the function of vascular endothelial cells in rats with hyperlipidemia. Chin. J. Exp. Traditional Med. Formulae 18 (13), 242&#x2013;244. 10.13422/j.cnki.syfjx.2012.13.076</Citation><ArticleIdList><ArticleId IdType="doi">10.13422/j.cnki.syfjx.2012.13.076</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X. Z. (2013). Discussion on the treatment of essential hypertension with the combination of valsartan and naoxinqing tablets. J. Clin. Ration. Drug Use 6 (05), 36&#x2013;37. 10.15887/j.cnki.13-1389/r.2013.05.090</Citation><ArticleIdList><ArticleId IdType="doi">10.15887/j.cnki.13-1389/r.2013.05.090</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S. W., Zhang M. Y., Liu Q. B., Luo S. Y., Peng Y., Sun B., et al. (2016). The effect of ethyl acetate extract from persimmon leaves on Alzheimer&#x2019;s disease and its underlying mechanism. Phytomedicine 23 (7), 694&#x2013;704. 10.1016/j.phymed.2016.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2016.03.009</ArticleId><ArticleId IdType="pubmed">27235708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y. F., Liu T. T., Fan W. J. (2024). Observation on the efficacy of naoxinqing capsules combined with metoprolol in the treatment of stable angina pectoris. Mod. Med. Clin. Appl. 39 (10), 2556&#x2013;2560.</Citation></Reference><Reference><Citation>Jung U. J., Park Y. B., Kim S. R., Choi M. S. (2012). Supplementation of persimmon leaf ameliorates hyperglycemia, dyslipidemia and hepatic fat accumulation in type 2 diabetic mice. PLoS One 7 (11), e49030. 10.1371/journal.pone.0049030</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049030</ArticleId><ArticleId IdType="pmc">PMC3493507</ArticleId><ArticleId IdType="pubmed">23145054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazzem M., Sun Y. T., Low M., Seto S. W., Chang D., Lee S., et al. (2019). Chromatographic analysis and anti-oxidative property of naoxinqing tablet, a proprietary preparation of Diospyros kaki leaves. Molecules 24 (6), 1101. 10.3390/molecules24061101</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24061101</ArticleId><ArticleId IdType="pmc">PMC6470564</ArticleId><ArticleId IdType="pubmed">30897753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G. Y., Kim J. K., Kang W. W., Kim J. G., Joo G. J. (2005). Shelf-life extension of rice cake by the addition of persimmon leaf tea powder. Food Sci. Biotechnol. 14 (2), 196&#x2013;199.</Citation></Reference><Reference><Citation>Kim A. H., Kim H. J., Ryu R., Han H. J., Han Y. J., Lee M. K., et al. (2016). A mixture of ethanol extracts of persimmon leaf and citrus junos sieb improves blood coagulation parameters and ameliorates lipid metabolism disturbances caused by diet-induced obesity in C57BL/6J mice. J. Microbiol. Biotechnol. 26 (2), 295&#x2013;308. 10.4014/jmb.1509.09050</Citation><ArticleIdList><ArticleId IdType="doi">10.4014/jmb.1509.09050</ArticleId><ArticleId IdType="pubmed">26699754</ArticleId></ArticleIdList></Reference><Reference><Citation>Klempfner R., Erez A., Sagit B. Z., Goldenberg I., Fisman E., Kopel E., et al. (2016). Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry. Circ. Cardiovasc Qual. Outcomes 9 (2), 100&#x2013;108. 10.1161/circoutcomes.115.002104</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circoutcomes.115.002104</ArticleId><ArticleId IdType="pubmed">26957517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamprecht D. G., Jr., Saseen J. J., Shaw P. B. (2022). Clinical conundrums involving statin drug-drug interactions. Prog. Cardiovasc Dis. 75, 83&#x2013;89. 10.1016/j.pcad.2022.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2022.11.002</ArticleId><ArticleId IdType="pubmed">36400235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. S., Lee M. K., Ha T. Y., Bok S. H., Park H. M., Jeong K. S., et al. (2006). Supplementation of whole persimmon leaf improves lipid profiles and suppresses body weight gain in rats fed high-fat diet. Food Chem. Toxicol. 44 (11), 1875&#x2013;1883. 10.1016/j.fct.2006.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2006.06.014</ArticleId><ArticleId IdType="pubmed">16904806</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Zhu Y., Zhang Y., Lang J., Chen Y., Ling W. (2013). Estimated daily flavonoid and stilbene intake from fruits, vegetables, and nuts and associations with lipid profiles in Chinese adults. J. Acad. Nutr. Diet. 113 (6), 786&#x2013;794. 10.1016/j.jand.2013.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jand.2013.01.018</ArticleId><ArticleId IdType="pubmed">23522824</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y. H., Wu G., Yang Z. J. (2013). Preparation of flavonoid sustained-release tablets from persimmon leaves and determination of their release rate. Chin. Propr. Med. 35 (10), 2134&#x2013;2137.</Citation></Reference><Reference><Citation>Liang Q., Cai Y., Chen R., Chen W., Chen L., Xiao Y. (2022). Effect of naoxinging tablet in the treatment of convalescent stroke: a multicenter, randomized, double-blind, control trial. Chin. Archives Traditional Chin. Med. 42 (07), 802&#x2013;810.</Citation></Reference><Reference><Citation>Liu F. R. (2019). Observation on the efficacy of naoxinqing in treating the elevated blood lipid levels in female schizophrenia patients caused by olanzapine. Prim. Med. Forum 23 (02), 165&#x2013;166. 10.19435/j.1672-1721.2019.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.19435/j.1672-1721.2019.02.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W. F. (2023). Improvement of the quality standards for naoxinqing tablets. Chin. Pat. Med. 45 (12), 3910&#x2013;3913.</Citation></Reference><Reference><Citation>Luo J., Xu T., Huang W. H., Li M. M. (2004). Research on the quality standards of naoxinqing tablets. Chin. J. New Drugs (07), 625&#x2013;627.</Citation></Reference><Reference><Citation>Lv X. W., Qu J. G., Dong W. T., Liu C. Y. (2020). Therapeutic effect of naoxinqing tablets combined with atorvastatin in patients with Acute cerebral infarction. J. Math. Med. 33 (08), 1188&#x2013;1189.</Citation></Reference><Reference><Citation>Mach F., Baigent C., Catapano A. L., Koskinas K. C., Casula M., Badimon L., et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41 (1), 111&#x2013;188. 10.1093/eurheartj/ehz455</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz455</ArticleId><ArticleId IdType="pubmed">31504418</ArticleId></ArticleIdList></Reference><Reference><Citation>Maitra U., Parks J. S., Li L. (2009). An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2. Mol. Cell Biol. 29 (22), 5989&#x2013;5997. 10.1128/mcb.00541-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.00541-09</ArticleId><ArticleId IdType="pmc">PMC2772564</ArticleId><ArticleId IdType="pubmed">19752193</ArticleId></ArticleIdList></Reference><Reference><Citation>Marston N. A., Giugliano R. P., Im K., Silverman M. G., O'Donoghue M. L., Wiviott S. D., et al. (2019). Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation 140 (16), 1308&#x2013;1317. 10.1161/circulationaha.119.041998</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.119.041998</ArticleId><ArticleId IdType="pmc">PMC6791781</ArticleId><ArticleId IdType="pubmed">31530008</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman C. B. (2022). Safety of statins and nonstatins for treatment of dyslipidemia. Endocrinol. Metab. Clin. North Am. 51 (3), 655&#x2013;679. 10.1016/j.ecl.2022.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ecl.2022.01.004</ArticleId><ArticleId IdType="pubmed">35963634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols G. A., Philip S., Reynolds K., Granowitz C. B., Fazio S. (2019). Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes. Metab. 21 (2), 366&#x2013;371. 10.1111/dom.13537</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13537</ArticleId><ArticleId IdType="pmc">PMC6587847</ArticleId><ArticleId IdType="pubmed">30225881</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan C. W., W. W., Xie Y. F., Qi X. Z., Jiang L. X. (2016). Effects of persimmon leaves on oxygen free radicals and lipid metabolism enzymes in rats with hyperlipidemia. Guid. J. Traditional Chin. Med. Pharm. 22 (20), 42&#x2013;44. 10.13862/j.cnki.cn43-1446/r.2016.20.015</Citation><ArticleIdList><ArticleId IdType="doi">10.13862/j.cnki.cn43-1446/r.2016.20.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirillo A., Casula M., Olmastroni E., Norata G. D., Catapano A. L. (2021). Global epidemiology of dyslipidaemias. Nat. Rev. Cardiol. 18 (10), 689&#x2013;700. 10.1038/s41569-021-00541-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00541-4</ArticleId><ArticleId IdType="pubmed">33833450</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao Z. L., Li X. F., Feng S. J., Yang J. X. (2013). Effects of naoxinqing tablets on patients with coronary atherosclerotic heart disease. New J. Traditional Chin. Med. 45 (09), 15&#x2013;16. 10.13457/j.cnki.jncm.2013.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.13457/j.cnki.jncm.2013.09.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-Briones E., Rodr&#xed;guez-Mac&#xed;as R., Salcedo-P&#xe9;rez E., Ram&#xed;rez-Ch&#xe1;vez E., Molina-Torres J., Tiessen A., et al. (2019). Seasonal changes in the metabolic profiles and biological activity in leaves of Diospyros digyna and D. Rekoi &#x201c;Zapote&#x201d; Trees. Plants (Basel) 8 (11), 449. 10.3390/plants8110449</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/plants8110449</ArticleId><ArticleId IdType="pmc">PMC6918230</ArticleId><ArticleId IdType="pubmed">31731430</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauf A., Uddin G., Patel S., Khan A., Halim S. A., Bawazeer S., et al. (2017). Diospyros, an under-utilized, multi-purpose plant genus: a review. Biomed. Pharmacother. 91, 714&#x2013;730. 10.1016/j.biopha.2017.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.05.012</ArticleId><ArticleId IdType="pubmed">28499243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruscica M., Macchi C., Morlotti B., Sirtori C. R., Magni P. (2014). Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur. J. Intern Med. 25 (5), 401&#x2013;406. 10.1016/j.ejim.2014.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2014.03.003</ArticleId><ArticleId IdType="pubmed">24685426</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakanaka S., Tachibana Y., Okada Y. (2005). Preparation and antioxidant properties of extracts of Japanese persimmon leaf tea (kakinoha-cha). Food Chem. 89 (4), 569&#x2013;575. 10.1016/j.foodchem.2004.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2004.03.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea B. J., Reeves B. C., Wells G., Thuku M., Hamel C., Moran J., et al. (2017). AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj 358, j4008. 10.1136/bmj.j4008</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j4008</ArticleId><ArticleId IdType="pmc">PMC5833365</ArticleId><ArticleId IdType="pubmed">28935701</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman M. G., Ference B. A., Im K., Wiviott S. D., Giugliano R. P., Grundy S. M., et al. (2016). Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316 (12), 1289&#x2013;1297. 10.1001/jama.2016.13985</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.13985</ArticleId><ArticleId IdType="pubmed">27673306</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroes E. S., Thompson P. D., Corsini A., Vladutiu G. D., Raal F. J., Ray K. K., et al. (2015). Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur. Heart J. 36 (17), 1012&#x2013;1022. 10.1093/eurheartj/ehv043</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv043</ArticleId><ArticleId IdType="pmc">PMC4416140</ArticleId><ArticleId IdType="pubmed">25694464</ArticleId></ArticleIdList></Reference><Reference><Citation>Su M. L. a.G. (1436). Southern Yunnan herbs. Kunming: Yunnan Science and Technology Press.</Citation></Reference><Reference><Citation>Tang B. S., Liang Z. W., Deng W. Q., Jiang Y. Z., Wu H. L., Chen B. (2012). 35 cases of naoxinqing tablets in adjuvant treatment of diabetic cerebral infarction. Glob. Tradit. Chin. Med. 5 (08), 616&#x2013;618.</Citation></Reference><Reference><Citation>Vaduganathan M., Mensah G. A., Turco J. V., Fuster V., Roth G. A. (2022). The Global Burden of cardiovascular diseases and risk: a compass for future health. J. Am. Coll. Cardiol. 80 (25), 2361&#x2013;2371. 10.1016/j.jacc.2022.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.11.005</ArticleId><ArticleId IdType="pubmed">36368511</ArticleId></ArticleIdList></Reference><Reference><Citation>Visseren F. L. J., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., B&#xe4;ck M., et al. (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42 (34), 3227&#x2013;3337. 10.1093/eurheartj/ehab484</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab484</ArticleId><ArticleId IdType="pubmed">34458905</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C. Y. a.W. L. (2016). Observation on the efficacy of naoxinqing combined with fluvastatin in the treatment of elderly lower extremity arteriosclerosis obliterans. Guide Chin. Med. 14 (28), 189&#x2013;190. 10.15912/j.cnki.gocm.2016.28.156</Citation><ArticleIdList><ArticleId IdType="doi">10.15912/j.cnki.gocm.2016.28.156</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. C. a. X. (2023). Expert consensus on the clinical application of naoxinqing tablets in treating ischemic cerebrovascular diseases. Chin. Archives Traditional Chin. Med. 41 (05), 247&#x2013;253. 10.13193/j.issn.1673-7717.2023.05.052</Citation><ArticleIdList><ArticleId IdType="doi">10.13193/j.issn.1673-7717.2023.05.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., O. Y., Liu J., Zhao G. (2014). Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies. Br. J. Nutr. 111 (1), 1&#x2013;11. 10.1017/s000711451300278x</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s000711451300278x</ArticleId><ArticleId IdType="pubmed">23953879</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. X. L., Tian Y., Li X. J., Wang L. Y., Wang L., Yang B. H., et al. (2023a). Flavonoids from persimmon leaves improve hepatic steatosis in rats with non-alcoholic fatty liver disease (NAFLD) by activating autophagy and synergistically acting on antioxidant stress. Tianjin Med. J. 51 (11), 1211&#x2013;1216.</Citation></Reference><Reference><Citation>Wang J. L., Li J. J., Wu G. P., Chen Z. Y., Zhao D., Zhao S. P., et al. (2023b). Chinese lipid management guidelines (2023). Chin. Circ. J. 38 (03), 237&#x2013;271.</Citation></Reference><Reference><Citation>Wei C., Cheng W. H., Han C. L. (2018). Research on the influence of persimmon leaf extract on blood lipid levels in elderly patients with primary hyperlipidemia. J. Math. Med. 31 (8), 1206&#x2013;1207. 10.3969/j.issn.1004-4337.2018.08.046</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1004-4337.2018.08.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong N. D., Budoff M. J., Ferdinand K., Graham I. M., Michos E. D., Reddy T., et al. (2022). Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement. Am. J. Prev. Cardiol. 10, 100335. 10.1016/j.ajpc.2022.100335</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpc.2022.100335</ArticleId><ArticleId IdType="pmc">PMC8943256</ArticleId><ArticleId IdType="pubmed">35342890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J. L. (2004). Clinical evaluation of naoxinqing tablets in the treatment of coronary heart disease with angina pectoris. Guangdong Pharm. J. (06), 41&#x2013;43.</Citation></Reference><Reference><Citation>Wu X. L., Wang M. J., Qi Y., Zhang W. J., Ao Q. X. (2008). Clinical study on the effects of naoxinqing tablets on blood lipids and blood viscosity. Chin. Herb. Med. (01), 171&#x2013;174. 10.13863/j.issn1001-4454.2008.01.061</Citation><ArticleIdList><ArticleId IdType="doi">10.13863/j.issn1001-4454.2008.01.061</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie C., Xie Z., Xu X., Yang D. (2015). Persimmon (Diospyros kaki L.) leaves: a review on traditional uses, phytochemistry and pharmacological properties. J. Ethnopharmacol. 163, 229&#x2013;240. 10.1016/j.jep.2015.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2015.01.007</ArticleId><ArticleId IdType="pubmed">25637828</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y. Q., Tan X. L., Zou J. K. (2013). Clinical analysis of integrated traditional Chinese and Western medicine therapy for unstable angina pectoris in elderly patients. Chin. Foreign Med. Res. (12), 36&#x2013;37.</Citation></Reference><Reference><Citation>Yang Z. Y., Ma C. H., Yuan M. Y., Yang Y., Wang Y. J., Liu L. H. (2014). Effects of persimmon leaf flavonoid preparations and simvastatin on serum inflammatory factors and lipoprotein(a) levels in hypertensive patients. Chin. J. Arteriosclerosis 22 (10), 1044&#x2013;1048.</Citation></Reference><Reference><Citation>Zhang S. T. a.L. C. (2021). Clinical study on naoxinqing capsules in delaying the progression of cerebral arteriosclerosis. World Latest Med. Inf. Abstr. 21 (34), 44&#x2013;46. 10.3969/j.issn.1671-3141.2021.34.016</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1671-3141.2021.34.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q. Y., Zhao Y. Y., Wang L., Wang H. L. (2005). The effects of persimmon leaf extracts on blood glucose and lipid levels in streptozotocin-induced diabetic mice. J. Third Mil. Med. Univ. 14, 1449&#x2013;1452.</Citation></Reference><Reference><Citation>Zhao L. D. a. H. C. (2015). Research on the preparation technology of ointment containing total flavonoids from persimmon leaves. Heilongjiang Animal Sci. Veterinary Med., 173&#x2013;175. 10.13881/j.cnki.hljxmsy.2015.0538</Citation><ArticleIdList><ArticleId IdType="doi">10.13881/j.cnki.hljxmsy.2015.0538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao R. F. (2016). Observation on the efficacy of naoxinqing tablets combined with cinnarizine in treating dizziness in patients with chronic cerebral hypoperfusion. Lingnan J. Emerg. Med. 21 (04), 381&#x2013;382.</Citation></Reference><Reference><Citation>Zhou X. W. a. H. (2023). Study on the effect of persimmon leaf total flavonoids in inhibiting lipid accumulation in macrophage-derived foam cells. J. Hubei Univ. Sci. Technol. 37 (05), 374&#x2013;378. 10.16751/j.cnki.2095-4646.2023.05.0374</Citation><ArticleIdList><ArticleId IdType="doi">10.16751/j.cnki.2095-4646.2023.05.0374</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X. C., Pan C. Q., Gao M. (2015). Observation on the efficacy of persimmon leaf extract in the secondary prevention of ischemic cerebrovascular diseases. Chin. J. Biochem. Pharmaceuticals Clin. 35 (04), 112&#x2013;115.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41031153</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Safety and effectiveness of apixaban use for stroke prevention during Ramadan fasting (the API-RAM study).</ArticleTitle><Pagination><StartPage>1565094</StartPage><MedlinePgn>1565094</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1565094</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2025.1565094</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Patients receiving anticoagulation for atrial fibrillation (AF) are required to consult their doctor before starting Ramadan fasting to get their authorization for fasting and adapt their treatment. More often, a once-daily regimen is proposed to facilitate their intake schedule. Apixaban, a direct oral anticoagulant, prescribed twice daily with an optimal benefit/risk ratio in numerous situations, has very limited data regarding its use during Ramadan.</AbstractText><AbstractText Label="AIM" NlmCategory="UNASSIGNED">The aim of this study was to evaluate the safety and the efficacy of apixaban for stroke prevention in AF patients during the month of Ramadan.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">An observational, multicentric study was performed in Tunisia during two consecutive years during the specific month of Ramadan. The API-RAM study included AF patients who were on apixaban and fasted at least 10&#xa0;days. Efficacy was defined by the absence of ischemic events, and safety was established by classifying bleeding events using the BARC (Bleeding Academic Research Consortium) classification during the study period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 257 patients were included in our study. No ischemic events were reported during the study period. Minor bleeding events were reported in only 12 patients (4.7%), with no major bleeding event. Based on multivariate analysis, independent predictors for the bleeding risk of our population were as follows: smoking, history of hypertension, and creatinine clearance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Apixaban seems to be safe and effective for the prevention of the thromboembolic episode in AF patients during Ramadan fasting. Larger studies such as randomized clinical trials are necessary to confirm these results.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Ghrab, Gargouri, Addad, Cheikhrouhou, Jabeur, Charfeddine, Bahloul, Triki, Ellouze, Abidi, Mallek, Triki, Abdessalem, Elalamy and Abid.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghrab</LastName><ForeName>Aiman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gargouri</LastName><ForeName>Rania</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Addad</LastName><ForeName>Faouzi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hannibal Clinic, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheikhrouhou</LastName><ForeName>Anis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jabeur</LastName><ForeName>Mariem</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charfeddine</LastName><ForeName>Selma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahloul</LastName><ForeName>Amine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triki</LastName><ForeName>Zied</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellouze</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abidi</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Hannibal Clinic, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallek</LastName><ForeName>Souad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triki</LastName><ForeName>Faten</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdessalem</LastName><ForeName>Salem</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinic Pasteur Tunis, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elalamy</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hematology Department, American Hospital of Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondation UPM des Sciences de la Sant&#xe9;, Marrakesh, Morocco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Perinatal Medicine, Sechenov University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abid</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ramadan</Keyword><Keyword MajorTopicYN="N">anticoagulants</Keyword><Keyword MajorTopicYN="N">apixaban</Keyword><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">fasting</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41031153</ArticleId><ArticleId IdType="pmc">PMC12476992</ArticleId><ArticleId IdType="doi">10.3389/fphar.2025.1565094</ArticleId><ArticleId IdType="pii">1565094</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Addad F., Amami M., Ibn Elhadj Z., Chakroun T., Marrakchi S., Kachboura S. (2014). Does ramadan fasting affect the intensity of acenocoumarol-induced anticoagulant effect? Br. J. Haematol. 166 (5), 792&#x2013;794. 10.1111/bjh.12897</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12897</ArticleId><ArticleId IdType="pubmed">24749553</ArticleId></ArticleIdList></Reference><Reference><Citation>
Agrawal A., Kerndt C. C., Manna B. (2024). &#x201c;Apixaban,&#x201d; in 
<i>StatPearls. Treasure Island</i>
, FL: StatPearls Publishing. Available online at: http://www.ncbi.nlm.nih.gov/books/NBK507910/(Accessed: January 4, 2025).</Citation></Reference><Reference><Citation>Akhtar A. M., Ghouri N., Chahal C. A. A., Patel R., Ricci F., Sattar N., et al. (2022). Ramadan fasting: recommendations for patients with cardiovascular disease. Heart 108 (4), 258&#x2013;265. 10.1136/heartjnl-2021-319273</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2021-319273</ArticleId><ArticleId IdType="pmc">PMC8819657</ArticleId><ArticleId IdType="pubmed">33990414</ArticleId></ArticleIdList></Reference><Reference><Citation>AlAyoubi F. (2021). The effect of ramadan fasting on oral anticoagulant: experience of tertiary academic hospital. Ann. Rev. and Res. 6 (3). 10.19080/ARR.2021.06.555688</Citation><ArticleIdList><ArticleId IdType="doi">10.19080/ARR.2021.06.555688</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ghumlas A. K. (2024). Ramadan intermittent fasting is associated with improved anticoagulant activity among healthy people: a case&#x2013;control study. Sci. Rep. 14 (1), 13855. 10.1038/s41598-024-64582-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-64582-8</ArticleId><ArticleId IdType="pmc">PMC11180170</ArticleId><ArticleId IdType="pubmed">38879576</ArticleId></ArticleIdList></Reference><Reference><Citation>Almulhem M., Susarla R., Alabdulaali L., Khunti K., Karamat M. A., Rasiah T., et al. (2020). The effect of ramadan fasting on cardiovascular events and risk factors in patients with type 2 diabetes: a systematic review. Diabetes Res. Clin. Pract. 159, 107918. 10.1016/j.diabres.2019.107918</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2019.107918</ArticleId><ArticleId IdType="pubmed">31711857</ArticleId></ArticleIdList></Reference><Reference><Citation>AlShoaibi N., Al Harbi M., Modaimegh H., Al Qubbany A., Al Saif S., Connolly D. L., et al. (2021). Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: perspectives on improving patient care. Expert Rev. Cardiovasc. Ther. 19 (3), 221&#x2013;236. 10.1080/14779072.2021.1878878</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14779072.2021.1878878</ArticleId><ArticleId IdType="pubmed">33475462</ArticleId></ArticleIdList></Reference><Reference><Citation>Anghel L. A., Farcas A. M., Oprean R. N. (2019). An overview of the common methods used to measure treatment adherence. Med. Pharm. Rep. 92 (2), 117&#x2013;122. 10.15386/mpr-1201</Citation><ArticleIdList><ArticleId IdType="doi">10.15386/mpr-1201</ArticleId><ArticleId IdType="pmc">PMC6510353</ArticleId><ArticleId IdType="pubmed">31086837</ArticleId></ArticleIdList></Reference><Reference><Citation>Batarfi A., Alenezi H., Alshehri A., Balelah S., Kazim H., Algthami M., et al. (2021). Patient-guided modifications of oral anticoagulant drug intake during ramadan fasting: a multicenter cross-sectional study. J. Thrombosis Thrombolysis 51 (2), 485&#x2013;493. 10.1007/s11239-020-02218-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02218-0</ArticleId><ArticleId IdType="pmc">PMC7886720</ArticleId><ArticleId IdType="pubmed">32666427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortman L. V., Mitchell F., Naveiro S., P&#xe9;rez Morales J., Gonzalez C. D., Di Girolamo G., et al. (2023). Direct oral anticoagulants: an updated systematic review of their clinical pharmacology and clinical effectiveness and safety in patients with nonvalvular atrial fibrillation. J. Clin. Pharmacol. 63 (4), 383&#x2013;396. 10.1002/jcph.2184</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.2184</ArticleId><ArticleId IdType="pubmed">36433678</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajos G., Konieczynska M., Zalewski J., Undas A. (2015). Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk. Cardiovasc. Diabetol. 14, 44. 10.1186/s12933-015-0207-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-015-0207-2</ArticleId><ArticleId IdType="pmc">PMC4432887</ArticleId><ArticleId IdType="pubmed">25928628</ArticleId></ArticleIdList></Reference><Reference><Citation>
Granger C. B., Alexander J. H., McMurray J. J. V., Lopes R. D., Hylek E. M., Hanna M., et al.  (2011). Apixaban <i>versus</i> warfarin in patients with atrial fibrillation. N. Engl. J. Med.
365 (11), 981&#x2013;992. 10.1056/NEJMoa1107039

</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1107039</ArticleId><ArticleId IdType="pubmed">21870978</ArticleId></ArticleIdList></Reference><Reference><Citation>Harskamp R. E., Lucassen W. A. M., Lopes R. D., Himmelreich J. C. L., Parati G., Weert H. C. P. M. v. (2022). Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiol. 77 (3), 191&#x2013;195. 10.1080/00015385.2021.1882111</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00015385.2021.1882111</ArticleId><ArticleId IdType="pubmed">33685380</ArticleId></ArticleIdList></Reference><Reference><Citation>Katada Y., Nakagawa S., Nishimura A., Sato Y. K., Taue H., Matsumura K., et al. (2019). Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery. Eur. J. Clin. Pharmacol. 75 (4), 561&#x2013;568. 10.1007/s00228-018-2592-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-018-2592-4</ArticleId><ArticleId IdType="pubmed">30460405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B. H., Joo Y., Kim M. S., Choe H. K., Tong Q., Kwon O. (2021). Effects of intermittent fasting on the circulating levels and circadian rhythms of hormones. Endocrinol. Metabolism 36 (4), 745&#x2013;756. 10.3803/EnM.2021.405</Citation><ArticleIdList><ArticleId IdType="doi">10.3803/EnM.2021.405</ArticleId><ArticleId IdType="pmc">PMC8419605</ArticleId><ArticleId IdType="pubmed">34474513</ArticleId></ArticleIdList></Reference><Reference><Citation>Langsted A., Nordestgaard B. G. (2018). Smoking is associated with increased risk of major bleeding: a prospective cohort study. Thrombosis Haemostasis 119, 39&#x2013;47. 10.1055/s-0038-1675798</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1675798</ArticleId><ArticleId IdType="pubmed">30597498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehran R., Rao S. V., Bhatt D. L., Gibson C. M., Caixeta A., Eikelboom J., et al. (2011). Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123 (23), 2736&#x2013;2747. 10.1161/CIRCULATIONAHA.110.009449</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.009449</ArticleId><ArticleId IdType="pubmed">21670242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirghani H. O., Faisal A. F. F., Salman A. W., Hussain G. A., Abdulaziz A. E., Muflih A. M., et al. (2023). Adherence to antidiabetic medication during the month of ramadan among diabetes mellitus patients in the Kingdom of Saudi Arabia. J. Adv. Zoology 44 (5), 747&#x2013;755. 10.53555/jaz.v44i5.3110</Citation><ArticleIdList><ArticleId IdType="doi">10.53555/jaz.v44i5.3110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouali S., Ben Halima A., Chabrak S., Chettaoui R., Ben Halima M., Haggui A., et al. (2021). Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA: results from the national Tunisian registry of atrial fibrillation (NATURE&#x2010;AF). Clin. Cardiol. 44 (4), 501&#x2013;510. 10.1002/clc.23558</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.23558</ArticleId><ArticleId IdType="pmc">PMC8027580</ArticleId><ArticleId IdType="pubmed">33704830</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#xf1;aloza-Mart&#xed;nez E., Moreno G., Aroca-Crevill&#xe9;n A., Huertas S., Vicent L., Rosillo N., et al. (2022). Circadian rhythms in thrombosis and atherothrombotic events. Front. Bioscience-Landmark 27 (2), 51. 10.31083/j.fbl2702051</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.fbl2702051</ArticleId><ArticleId IdType="pubmed">35226994</ArticleId></ArticleIdList></Reference><Reference><Citation>Rad M. S. (2023). Ramadan fasting as a goal-pursuit: why people fast, and how motives affect their experience. Motivation Sci. 9, 327&#x2013;339. 10.1037/mot0000310</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/mot0000310</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosca C. I., Sharma A., Nisulescu D. D., Otiman G., Duda-Seiman D. M., Morariu S. I., et al. (2023). Prevalence of cardio-embolic brain complications in permanent and paroxysmal atrial fibrillation patients. Healthcare 11 (2), 175. 10.3390/healthcare11020175</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare11020175</ArticleId><ArticleId IdType="pmc">PMC9858915</ArticleId><ArticleId IdType="pubmed">36673543</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandrini L., Ieraci A., Amadio P., Zar&#xe0; M., Barbieri S. S. (2020). Impact of acute and chronic stress on thrombosis in healthy individuals and cardiovascular disease patients. Int. J. Mol. Sci. 21 (21), 7818. 10.3390/ijms21217818</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21217818</ArticleId><ArticleId IdType="pmc">PMC7659944</ArticleId><ArticleId IdType="pubmed">33105629</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoeb M., Fang M. C. (2013). Assessing bleeding risk in patients taking anticoagulants. J. thrombosis thrombolysis 35 (3), 312&#x2013;319. 10.1007/s11239-013-0899-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-013-0899-7</ArticleId><ArticleId IdType="pmc">PMC3888359</ArticleId><ArticleId IdType="pubmed">23479259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridharan K., Al Banna R., Qader A. M., Husain A. (2021). Does fasting during ramadan influence the therapeutic effect of warfarin? J. Clin. Pharm. Ther. 46 (1), 86&#x2013;92. 10.1111/jcpt.13254</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpt.13254</ArticleId><ArticleId IdType="pubmed">32926452</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabelsi K., Ammar A., Boujelbane M. A., Puce L., Garbarino S., Scoditti E., et al. (2022). Religious fasting and its impacts on individual, public, and planetary health: fasting as a &#x201c;religious health asset&#x201d; for a healthier, more equitable, and sustainable society. Front. Nutr. 9, 1036496. 10.3389/fnut.2022.1036496</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.1036496</ArticleId><ArticleId IdType="pmc">PMC9729557</ArticleId><ArticleId IdType="pubmed">36505246</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrijens B., Heidbuchel H. (2015). Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. EP Eur. 17 (4), 514&#x2013;523. 10.1093/europace/euu311</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euu311</ArticleId><ArticleId IdType="pubmed">25694538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Chang A. R., Inker L. A., McAdams-DeMarco M., Grams M. E., Shin J. I. (2023). Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. Circulation 148 (19), 1445&#x2013;1454. 10.1161/CIRCULATIONAHA.123.065614</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.123.065614</ArticleId><ArticleId IdType="pmc">PMC10840683</ArticleId><ArticleId IdType="pubmed">37681341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz T. (2023). Evaluation of medication adherence of individuals with chronic diseases during ramadan. Ankara Med. J. 23 (3), 344&#x2013;356. 10.5505/amj.2023.70842</Citation><ArticleIdList><ArticleId IdType="doi">10.5505/amj.2023.70842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zghal Mghaieth F., Bonkano A., Boudiche S., Ayari J., Ben Mansour N., Rekik B., et al. (2019). Oral anticoagulation therapy using acenocoumarol during the month of ramadan: a comparative study between fasting and non-fasting patients. La Tunis. Medicale 97 (10), 1177&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">31691946</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41028404</PMID><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1619-1560</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Clinical autonomic research : official journal of the Clinical Autonomic Research Society</Title><ISOAbbreviation>Clin Auton Res</ISOAbbreviation></Journal><ArticleTitle>Improvement in nocturnal blood pressure with bedtime antihypertensive administration in older adults aged 65 and above: a systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10286-025-01159-z</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study evaluated the effectiveness of morning versus bedtime antihypertensive medication administration in reducing ambulatory blood pressure (BP) in older adults aged&#x2009;&#x2265;&#x2009;65, and to assess whether administration timing influences conversion from a non-dipper to a dipper BP profile.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eight randomized controlled trials were identified through systematically screening of the PubMed and Web of Science databases. Risk of bias was assessed using the Cochrane Risk of Bias tool. Meta-analyses were conducted with Review Manager version 5.4 to compare the efficacy of morning versus bedtime administration on ambulatory BP indices.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bedtime administration resulted in significantly greater reductions in nocturnal systolic BP (mean difference [MD] -&#x2009;4.52&#xa0;mmHg, [lower and upper 95% confidence intervals [CI]&#x2009;-&#x2009;7.15;&#x2009;-&#x2009;1.90]; p&#x2009;=&#x2009;0.0007) and diastolic BP (MD -&#x2009;2.00&#xa0;mmHg, [95%&#xa0;CI&#x2009;-&#x2009;2.90;&#x2009;-&#x2009;1.10]; p&#x2009;&lt;&#x2009;0.0001). No significant differences were observed in diurnal systolic BP (MD 1.28&#xa0;mmHg, [95%&#xa0;CI&#x2009;-&#x2009;0.17; 2.72]; p&#x2009;=&#x2009;0.08), diastolic BP (MD 0.34&#xa0;mmHg, [95%&#xa0;CI&#x2009;-&#x2009;0.49; 1.16]; p&#x2009;=&#x2009;0.42), 24/48-h systolic BP (MD -&#x2009;0.02&#xa0;mmHg, [95%&#xa0;CI&#x2009;-&#x2009;1.37; 1.33]; p&#x2009;=&#x2009;0.98), or 24/48-h diastolic BP (MD -&#x2009;0.50&#xa0;mmHg, [95%&#xa0;CI&#x2009;-&#x2009;1.45; 0.45]; p&#x2009;=&#x2009;0.30). Sensitivity analysis excluding the controversial data from Hermida confirmed significantly greater reductions in nocturnal systolic and diastolic BP with bedtime administration. Two of three studies reported that bedtime administration was associated with a lower proportion of non-dippers than morning treatment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Bedtime antihypertensive administration improves control of nocturnal BP in older adults aged&#x2009;&#x2265;&#x2009;65 and may facilitate restoration to a dipper BP profile. No significant differences were observed in diurnal or 24/48-h mean BP reductions compared with morning administration.</AbstractText><CopyrightInformation>&#xa9; 2025. Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saren</LastName><ForeName>Jordy</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0008-1455-7658</Identifier><AffiliationInfo><Affiliation>Geriatrics Department, Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gerontology Department, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Frailty &amp; Resilience in Ageing (FRIA) Research Group, Vitality Group, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nursing and Midwifery Research Group (NUMID), Primary Care (PRIM), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieten</LastName><ForeName>Siddhartha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8825-8764</Identifier><AffiliationInfo><Affiliation>Geriatrics Department, Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Frailty &amp; Resilience in Ageing (FRIA) Research Group, Vitality Group, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrovic</LastName><ForeName>Mirko</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7506-8646</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Paediatrics, Section of Geriatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islamaj</LastName><ForeName>Esma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7437-5716</Identifier><AffiliationInfo><Affiliation>Department of Electronics and Informatics, Vrije Universiteit Brussel, Pleinlaan 2, 1050, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bautmans</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-6820-9586</Identifier><AffiliationInfo><Affiliation>Geriatrics Department, Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gerontology Department, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Frailty &amp; Resilience in Ageing (FRIA) Research Group, Vitality Group, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatric Physiotherapy, SOMT University of Physiotherapy, Softwareweg 5, 3821 BN, Amersfoort, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debain</LastName><ForeName>Aziz</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5752-6498</Identifier><AffiliationInfo><Affiliation>Geriatrics Department, Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium. Aziz.Debain@uzbrussel.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gerontology Department, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090, Brussels, Belgium. Aziz.Debain@uzbrussel.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Frailty &amp; Resilience in Ageing (FRIA) Research Group, Vitality Group, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090, Brussels, Belgium. Aziz.Debain@uzbrussel.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Auton Res</MedlineTA><NlmUniqueID>9106549</NlmUniqueID><ISSNLinking>0959-9851</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aged</Keyword><Keyword MajorTopicYN="N">Ambulatory</Keyword><Keyword MajorTopicYN="N">Antihypertensive agents</Keyword><Keyword MajorTopicYN="N">Blood pressure monitoring</Keyword><Keyword MajorTopicYN="N">Chronotherapy</Keyword><Keyword MajorTopicYN="N">Circadian rhythm</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword></KeywordList><CoiStatement>Declarations. Conflicts of interest: The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41028404</ArticleId><ArticleId IdType="doi">10.1007/s10286-025-01159-z</ArticleId><ArticleId IdType="pii">10.1007/s10286-025-01159-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fuchs FD, Whelton PK (2020) High blood pressure and cardiovascular disease. Hypertension 75:285&#x2013;292</Citation><ArticleIdList><ArticleId IdType="pubmed">31865786</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.119.14240</ArticleId></ArticleIdList></Reference><Reference><Citation>Glazier JJ (2022) Pathophysiology, diagnosis, and management of hypertension in the elderly. Int J Angiol 31:222&#x2013;228</Citation><ArticleIdList><ArticleId IdType="pubmed">36588864</ArticleId><ArticleId IdType="pmc">9803548</ArticleId><ArticleId IdType="doi">10.1055/s-0042-1759486</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia G, Kreutz R, Brunstr&#xf6;m M et al (2023) 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 41:1874&#x2013;2071</Citation><ArticleIdList><ArticleId IdType="pubmed">37345492</ArticleId><ArticleId IdType="doi">10.1097/HJH.0000000000003480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K (2018) Nocturnal hypertension. Hypertension 71:997&#x2013;1009</Citation><ArticleIdList><ArticleId IdType="pubmed">29712746</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.118.10971</ArticleId></ArticleIdList></Reference><Reference><Citation>Chotruangnapa C, Tansakun T, Roubsanthisuk W (2021) Clinical risk factors and predictive score for the non-dipper profile in hypertensive patients: a case-control study. Clin Hypertens 27:22</Citation><ArticleIdList><ArticleId IdType="pubmed">34776006</ArticleId><ArticleId IdType="pmc">8591836</ArticleId><ArticleId IdType="doi">10.1186/s40885-021-00180-4</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien E, Parati G, Stergiou G et al (2013) European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 31:1731&#x2013;1768</Citation><ArticleIdList><ArticleId IdType="pubmed">24029863</ArticleId><ArticleId IdType="doi">10.1097/HJH.0b013e328363e964</ArticleId></ArticleIdList></Reference><Reference><Citation>Huart J, Persu A, Lengel&#xe9; JP, Krzesinski JM, Jouret F, Stergiou GS (2023) Pathophysiology of the nondipping blood pressure pattern. Hypertension 80:719&#x2013;729</Citation><ArticleIdList><ArticleId IdType="pubmed">36606502</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.122.19996</ArticleId></ArticleIdList></Reference><Reference><Citation>Larochelle P (2002) Circadian variation in blood pressure: dipper or nondipper. J Clin Hypertens (Greenwich) 4:3&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">12147922</ArticleId><ArticleId IdType="doi">10.1111/j.1524-6175.2002.01033.x</ArticleId></ArticleIdList></Reference><Reference><Citation>El&#xe7;ik D, Duran M, Kele&#x15f;o&#x11f;lu &#x15e; et al (2021) Effect of nondipper hypertension on coronary artery disease progression in patients with chronic coronary syndrome. Turk J Med Sci 51:1273&#x2013;1280</Citation><ArticleIdList><ArticleId IdType="pubmed">33453712</ArticleId><ArticleId IdType="pmc">8283452</ArticleId><ArticleId IdType="doi">10.3906/sag-2011-225</ArticleId></ArticleIdList></Reference><Reference><Citation>Habas E Sr, Akbar RA, Alfitori G et al (2023) Effects of nondipping blood pressure changes: a nephrologist prospect. Cureus 15:e42681</Citation><ArticleIdList><ArticleId IdType="pubmed">37649932</ArticleId><ArticleId IdType="pmc">10464654</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021&#x2013;3104</Citation><ArticleIdList><ArticleId IdType="pubmed">30165516</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehy339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed A, Ruzieh M, Kanjwal S, Kanjwal K (2020) Syndrome of supine hypertension with orthostatic hypotension: pathophysiology and clinical approach. Curr Cardiol Rev 16:48&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pubmed">31215392</ArticleId><ArticleId IdType="pmc">7393597</ArticleId><ArticleId IdType="doi">10.2174/1573403X15666190617095032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K (2018) Nocturnal hypertension: new technology and evidence. Hypertension 71:997&#x2013;1009</Citation><ArticleIdList><ArticleId IdType="pubmed">29712746</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.118.10971</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassi G, Seravalle G, Quarti-Trevano F et al (2008) Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 52:925&#x2013;931</Citation><ArticleIdList><ArticleId IdType="pubmed">18779438</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.108.116368</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachdeva A, Weder AB (2006) Nocturnal sodium excretion, blood pressure dipping, and sodium sensitivity. Hypertension 48:527&#x2013;533</Citation><ArticleIdList><ArticleId IdType="pubmed">16940213</ArticleId><ArticleId IdType="doi">10.1161/01.HYP.0000240268.37379.7c</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzu T, Kimura G, Yamauchi A et al (2006) Enhanced sodium sensitivity and disturbed circadian rhythm of blood pressure in essential hypertension. J Hypertens 24:1627&#x2013;1632</Citation><ArticleIdList><ArticleId IdType="pubmed">16877966</ArticleId><ArticleId IdType="doi">10.1097/01.hjh.0000239299.71001.77</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieten S, Debain A, Bravenboer B, Mets T (2021) Inverted circadian variation of arterial pressure in a geriatric patient: an indicator of autonomic dysfunction. BMC Geriatr 21:148</Citation><ArticleIdList><ArticleId IdType="pubmed">33648443</ArticleId><ArticleId IdType="pmc">7919995</ArticleId><ArticleId IdType="doi">10.1186/s12877-021-02059-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Camafort M, Chung W-J, Shin J-H (2022) Role of ambulatory blood pressure monitoring in elderly hypertensive patients. Clin Hypertens 28:22</Citation><ArticleIdList><ArticleId IdType="pubmed">35773739</ArticleId><ArticleId IdType="pmc">9248111</ArticleId><ArticleId IdType="doi">10.1186/s40885-022-00205-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahabala C, Kamath P, Bhaskaran U, Pai ND, Pai AU (2013) Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently? Vasc Health Risk Manag 9:125&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">23569382</ArticleId><ArticleId IdType="pmc">3616131</ArticleId><ArticleId IdType="doi">10.2147/VHRM.S33515</ArticleId></ArticleIdList></Reference><Reference><Citation>He FJ, Markandu ND, MacGregor GA (2005) Modest salt reduction lowers blood pressure in isolated systolic hypertension and combined hypertension. Hypertension 46:66&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pubmed">15956111</ArticleId><ArticleId IdType="doi">10.1161/01.HYP.0000171474.84969.7a</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T-C, Lu Y-H, Chao C-T et al (2024) Comprehensive assessment and management of hypertension in elderly patients: addressing frailty and target organ damage. J Formosan Med Assoc 124:S17&#x2013;S23</Citation><ArticleIdList><ArticleId IdType="pubmed">39477698</ArticleId><ArticleId IdType="doi">10.1016/j.jfma.2024.10.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A, Toda T, Fujii T, Matsui N (2009) Bedtime administration of long-acting antihypertensive drugs restores normal nocturnal blood pressure fall in nondippers with essential hypertension. Clin Exp Nephrol 13:467&#x2013;472</Citation><ArticleIdList><ArticleId IdType="pubmed">19449087</ArticleId><ArticleId IdType="doi">10.1007/s10157-009-0184-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Maqsood MH, Messerli FH, Skolnick AH, Newman JD, Berger JS, Bangalore S (2023) Timing of antihypertensive drug therapy: a systematic review and meta-analysis of randomized clinical trials. Hypertension 80:1544&#x2013;1554</Citation><ArticleIdList><ArticleId IdType="pubmed">37212152</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.122.20862</ArticleId></ArticleIdList></Reference><Reference><Citation>Zannad F, Matzinger A, Larch&#xe9; J (1996) Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 9:633&#x2013;643</Citation><ArticleIdList><ArticleId IdType="pubmed">8806975</ArticleId><ArticleId IdType="doi">10.1016/0895-7061(96)00021-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiavo JH (2019) PROSPERO: an international register of systematic review protocols. Med Ref Serv Q 38:171&#x2013;180</Citation><ArticleIdList><ArticleId IdType="pubmed">31173570</ArticleId><ArticleId IdType="doi">10.1080/02763869.2019.1588072</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71</Citation><ArticleIdList><ArticleId IdType="pubmed">33782057</ArticleId><ArticleId IdType="pmc">8005924</ArticleId><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D (2020) A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract 21:496&#x2013;498</Citation><ArticleIdList><ArticleId IdType="pubmed">31874567</ArticleId><ArticleId IdType="doi">10.1177/1524839919893361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohishi M, Kawai T, Hayashi N et al (2013) Effect of tablets with a combination of telmisartan and amlodipine on patients with hypertension: the Cotalo study. Hypertens Res 36:620&#x2013;626</Citation><ArticleIdList><ArticleId IdType="pubmed">23425955</ArticleId><ArticleId IdType="doi">10.1038/hr.2013.10</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan&#x2014;a web and mobile app for systematic reviews. Syst Rev 5:210</Citation><ArticleIdList><ArticleId IdType="pubmed">27919275</ArticleId><ArticleId IdType="pmc">5139140</ArticleId><ArticleId IdType="doi">10.1186/s13643-016-0384-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13</Citation><ArticleIdList><ArticleId IdType="pubmed">15840177</ArticleId><ArticleId IdType="pmc">1097734</ArticleId><ArticleId IdType="doi">10.1186/1471-2288-5-13</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC et al (2011) The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ 343:d5928</Citation><ArticleIdList><ArticleId IdType="pubmed">22008217</ArticleId><ArticleId IdType="pmc">3196245</ArticleId><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan SE, Johnston RV (2023) Research note: interpreting findings of a systematic review using GRADE methods. J Physiother 69:198&#x2013;202</Citation><ArticleIdList><ArticleId IdType="pubmed">37277291</ArticleId><ArticleId IdType="doi">10.1016/j.jphys.2023.05.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaboration TC (2020) Review Manager (RevMan) [Computer program]. Version 5.4</Citation></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J et al (editors) (2022) Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated August 2022). Cochrane Collaboration</Citation></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J et al (editors) (2021) Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane Collaboration</Citation></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557&#x2013;560</Citation><ArticleIdList><ArticleId IdType="pubmed">12958120</ArticleId><ArticleId IdType="pmc">192859</ArticleId><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermida RC, Calvo C, Ayala DE et al (2005) Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol Int 22:755&#x2013;776</Citation><ArticleIdList><ArticleId IdType="pubmed">16147905</ArticleId><ArticleId IdType="doi">10.1080/07420520500180488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino A, Nakamura T, Matsubara H (2010) The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy. Clin Exp Hypertens 32:416&#x2013;422</Citation><ArticleIdList><ArticleId IdType="pubmed">20828223</ArticleId><ArticleId IdType="doi">10.3109/10641961003667948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K, Hoshide S, Uchiyama K et al (2016) Dose timing of an angiotensin II receptor blocker/calcium channel blocker combination in hypertensive patients with paroxysmal atrial fibrillation. J Clin Hypertens (Greenwich) 18:1036&#x2013;1044</Citation><ArticleIdList><ArticleId IdType="pubmed">26989846</ArticleId><ArticleId IdType="doi">10.1111/jch.12814</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan T, Anderson A, Jones E (1997) The effect on 24&#xa0;h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens 15:205&#x2013;211</Citation><ArticleIdList><ArticleId IdType="pubmed">9469797</ArticleId><ArticleId IdType="doi">10.1097/00004872-199715020-00012</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman M, Greene T, Phillips RA, et al.3rd, Rostand S, Toto R, Wang X, Wright JT Jr, Appel LJ (2013) A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension 61:82&#x2013;88</Citation><ArticleIdList><ArticleId IdType="pubmed">23172931</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.112.200477</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossen NB, Knudsen ST, Fleischer J et al (2014) Targeting nocturnal hypertension in type&#xa0;2 diabetes mellitus. Hypertension 64:1080&#x2013;1087</Citation><ArticleIdList><ArticleId IdType="pubmed">25259747</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.114.03958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J, Jia M, Ran H et al (2011) Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study. Hypertens Res 34:767&#x2013;772</Citation><ArticleIdList><ArticleId IdType="pubmed">21471971</ArticleId><ArticleId IdType="doi">10.1038/hr.2011.36</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermida RC, Ayala DE, Moj&#xf3;n A, Fern&#xe1;ndez JR (2010) Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 27:1629&#x2013;1651</Citation><ArticleIdList><ArticleId IdType="pubmed">20854139</ArticleId><ArticleId IdType="doi">10.3109/07420528.2010.510230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermida RC, Crespo JJ, Dom&#xed;nguez-Sardi&#xf1;a M et al (2020) Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia chronotherapy trial. Eur Heart J 41:4565&#x2013;4576</Citation><ArticleIdList><ArticleId IdType="pubmed">31641769</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehz754</ArticleId></ArticleIdList></Reference><Reference><Citation>Turgeon RD, Althouse AD, Cohen JB et al (2021) Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: controversies in hypertension - con side of the argument. Hypertension 78:871&#x2013;878</Citation><ArticleIdList><ArticleId IdType="pubmed">34379435</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.121.16501</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IS, Rogers A, Poulter NR et al (2022) Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet 400:1417&#x2013;1425</Citation><ArticleIdList><ArticleId IdType="pubmed">36240838</ArticleId><ArticleId IdType="pmc">9631239</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)01786-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Ihm S-H, Cho I-J et al (2023) Statement on chronotherapy for the treatment of hypertension: consensus document from the Korean Society of Hypertension. Clin Hypertens 29:25</Citation><ArticleIdList><ArticleId IdType="pubmed">37653547</ArticleId><ArticleId IdType="pmc">10472721</ArticleId><ArticleId IdType="doi">10.1186/s40885-023-00249-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo SH, Chau JP, Woo J, Thompson DR, Choi KC (2016) Adherence to antihypertensive medication in older adults with hypertension. J Cardiovasc Nurs 31:296&#x2013;303</Citation><ArticleIdList><ArticleId IdType="pubmed">25774846</ArticleId><ArticleId IdType="pmc">4915757</ArticleId><ArticleId IdType="doi">10.1097/JCN.0000000000000251</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashmi SK, Afridi MB, Abbas K et al (2007) Factors associated with adherence to anti-hypertensive treatment in Pakistan. PLoS ONE 2:e280</Citation><ArticleIdList><ArticleId IdType="pubmed">17356691</ArticleId><ArticleId IdType="pmc">1805684</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0000280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjeldsen SE, Egan BM, Narkiewicz K et al (2023) TIME to face the reality about evening dosing of antihypertensive drugs in hypertension. Blood Press 32(1):3</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08037051.2022.2142512</ArticleId></ArticleIdList></Reference><Reference><Citation>Omboni S, Bilo G, Saladini F et al (2024) Standards for the implementation, analysis, interpretation, and reporting of 24-hour ambulatory blood pressure monitoring recommendations of the Italian Society of Hypertension. High Blood Press Cardiovasc Prev 31:425&#x2013;436</Citation><ArticleIdList><ArticleId IdType="pubmed">39361086</ArticleId><ArticleId IdType="pmc">11485039</ArticleId><ArticleId IdType="doi">10.1007/s40292-024-00670-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena-Hernandez C, Nugent K, Tuncel M (2020) Twenty-four-hour ambulatory blood pressure monitoring. J Prim Care Community Health 11:2150132720940519</Citation><ArticleIdList><ArticleId IdType="pubmed">32646277</ArticleId><ArticleId IdType="pmc">7356999</ArticleId><ArticleId IdType="doi">10.1177/2150132720940519</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Sierra A, Banegas JR, Vinyoles E et al (2018) Prevalence of masked hypertension in untreated and treated patients with office blood pressure below 130/80 mm Hg. Circulation 137:2651&#x2013;2653</Citation><ArticleIdList><ArticleId IdType="pubmed">29712713</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.034619</ArticleId></ArticleIdList></Reference><Reference><Citation>Benetos A, Petrovic M, Strandberg T (2019) Hypertension management in older and frail older patients. Circ Res 124:1045&#x2013;1060</Citation><ArticleIdList><ArticleId IdType="pubmed">30920928</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.118.313236</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan BM, Mattix-Kramer HJ, Basile JN, Sutherland SE (2024) Managing hypertension in older adults. Curr Hypertens Rep 26:157&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pubmed">38150080</ArticleId><ArticleId IdType="doi">10.1007/s11906-023-01289-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Parati G, Bilo G (2009) Should 24-h ambulatory blood pressure monitoring be done in every patient with diabetes? Diabetes Care 32(Suppl 2):S298-304</Citation><ArticleIdList><ArticleId IdType="pubmed">19875569</ArticleId><ArticleId IdType="pmc">2811450</ArticleId><ArticleId IdType="doi">10.2337/dc09-S326</ArticleId></ArticleIdList></Reference><Reference><Citation>Proen&#xe7;a M, Amb&#xfc;hl J, Bonnier G et al (2023) Method-comparison study between a watch-like sensor and a cuff-based device for 24-h ambulatory blood pressure monitoring. Sci Rep 13:6149</Citation><ArticleIdList><ArticleId IdType="pubmed">37061569</ArticleId><ArticleId IdType="pmc">10105693</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-33205-z</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41027625</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-9906</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>NeoReviews</Title><ISOAbbreviation>Neoreviews</ISOAbbreviation></Journal><ArticleTitle>Pharmacology in Congenital Diaphragmatic Hernia: A Focus on Cardiovascular Management.</ArticleTitle><Pagination><StartPage>e660</StartPage><EndPage>e678</EndPage><MedlinePgn>e660-e678</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1542/neo.26-10-060</ELocationID><Abstract><AbstractText>Congenital diaphragmatic hernia (CDH) presents a complex challenge in neonatal care, requiring tailored pharmacological strategies to manage its distinct cardiorespiratory pathophysiology. CDH is commonly associated with pulmonary hypertension, impaired myocardial function, and adverse cardiorespiratory interactions, contributing to significant morbidity and mortality. Effective pharmacotherapy must address these interconnected factors while minimizing complications or side effects. Despite limited randomized controlled trial data specific to CDH, recent reports highlight the benefits of a precision medicine approach, focusing on individualized treatments based on evolving pathophysiology. Therapeutic interventions primarily involve pulmonary vasodilators, inotropes and vasopressors, prostaglandins, and corticosteroids; each agent has a distinct physiologic effect, and use needs to be tailored to the specific patient pathophysiology. Targeted neonatal echocardiography has emerged as a valuable tool for optimizing treatment decisions by providing real-time insights into ventricular performance and hemodynamic status. In this review, we explore the shift from a generalized pharmacological approach to targeted interventions based on evolving patient physiology. We discuss key therapeutic principles and the role of different drug classes in optimizing the management of infants with CDH throughout their intensive care journey.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 by the American Academy of Pediatrics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lapointe</LastName><ForeName>Anie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neonatology, CHU Sainte-Justine, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipfmueller</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neonatology and Pediatric Intensive Care Medicine, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neonatology, Royal Hospital for Children, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altit</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Neonatology, Montreal Children's Hospital, McGill University Health Centre Research Institute, Montreal, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neoreviews</MedlineTA><NlmUniqueID>101085360</NlmUniqueID><ISSNLinking>1526-9906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065630" MajorTopicYN="Y">Hernias, Diaphragmatic, Congenital</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41027625</ArticleId><ArticleId IdType="doi">10.1542/neo.26-10-060</ArticleId><ArticleId IdType="pii">204471</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>